Business Context and Reporting Period
This Form 8-K Current Report was filed by Verrica Pharmaceuticals Inc. on July 22, 2025. The report details a material modification to the rights of security holders, specifically the implementation of a reverse stock split authorized by stockholders at the Annual Meeting on June 5, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and capital structure adjustments.
Material Changes
- Reverse Stock Split: A 1-for-10 reverse stock split was effected via a Certificate of Amendment filed with the Delaware Secretary of State.
- Effective Date: The split became effective at 5:00 p.m. Eastern Time on July 24, 2025.
- Share Count Adjustment: As of July 11, 2025, there were approximately 92.5 million shares outstanding. Immediately following the split, this is expected to reduce to approximately 9.25 million shares.
- Trading Details: Trading on The Nasdaq Global Market resumed on a split-adjusted basis on July 25, 2025, under the new CUSIP number 92511W207.
- Derivative Adjustments: Exercise prices and share counts for outstanding stock options and warrants were adjusted proportionately. No fractional shares were issued; cash payments were made in lieu thereof.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on business outlook, or specific risk factors beyond the standard implications of a reverse stock split. The primary contingency noted is the cashing out of fractional shares, which may cause minor variations in the final post-split share count.
Investor Verification Checklist
- Verify the new CUSIP number (92511W207) for trading purposes.
- Confirm the adjusted number of shares held in brokerage accounts post-split.
- Review the adjusted exercise prices and share quantities for any held stock options or warrants.
- Check for cash payments received in lieu of fractional shares.